Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million

3 weeks ago 20

Jonathan Ponciano, The Motley Fool

Fri, February 27, 2026 astatine 10:12 AM CST 4 min read

Casdin Capital reduced its involvement successful Structure Therapeutics (NASDAQ:GPCR) by 380,000 shares successful the 4th quarter, an estimated $15.52 cardinal commercialized based connected quarterly mean pricing, per a February 17, 2026, SEC filing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Casdin Capital sold 380,000 shares of Structure Therapeutics during the 4th quarter. The estimated worth of this commercialized is $15.52 cardinal based connected the period’s mean stock price. The quarter-end presumption worth shifted by $38.18 million, a fig that incorporates some trading enactment and changes successful marketplace value.

This was a simplification successful holdings; Structure Therapeutics accounted for 5.08% of Casdin’s 13F assets aft the sale.
Top 5 holdings aft the filing:
- NASDAQ:WGS: $391.11 cardinal (24.3% of AUM)
- NASDAQ:RVMD: $205.28 cardinal (12.8% of AUM)
- NASDAQ:BLFS: $144.04 cardinal (8.9% of AUM)
- NASDAQ:LAB: $113.64 cardinal (7.1% of AUM)
- NASDAQ:RLAY: $110.01 cardinal (6.8% of AUM)
As of February 17, 2026, GPCR shares were priced astatine $71.41, up 214.3% implicit the past twelvemonth and vastly outperforming the S&P 500 by 180.87 percent points.

Metric

Value

Price (as of marketplace adjacent 2026-02-17)	$71.41
Market Capitalization	$4.11 billion
Net Income (TTM)	($210.69 million)
One-Year Price Change	214.30%

Structure develops oral therapeutics targeting chronic diseases, with a pb campaigner (GSBR-1290) focused connected type-2 diabetes and obesity; further pipeline assets code pulmonary and cardiovascular conditions.
The steadfast operates a clinical-stage biopharmaceutical model, generating worth done cause improvement and imaginable out-licensing oregon commercialization partnerships; gross is not yet realized arsenic products stay successful objective trials.
It targets patients with chronic metabolic, pulmonary, and cardiovascular diseases, chiefly addressing unmet needs successful the healthcare and biotechnology markets.

Structure Therapeutics Inc. is simply a clinical-stage biotechnology institution specializing successful the improvement of caller oral therapeutics for chronic diseases with important unmet aesculapian needs. The institution leverages expertise successful G-protein-coupled receptor (GPCR) cause find to beforehand a pipeline led by GSBR-1290 for type-2 diabetes and obesity, alongside candidates for pulmonary and cardiovascular indications.

With a absorption connected innovative, orally delivered tiny molecules, Structure Therapeutics aims to supply differentiated attraction options that code some efficacy and diligent convenience, positioning itself competitively successful the evolving biopharmaceutical landscape.

Read Entire Article